[{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amlodipine Besylate","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CMP Pharma, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CMP Pharma, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CMP Pharma, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CMP Pharma, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CMP Pharma, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CMP Pharma, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Potassium Phosphate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"CMP Pharma, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"CMP Pharma, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CMP Pharma, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CMP Pharma, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CMP Pharma, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CMP Pharma, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atorvastatin","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CMP Pharma, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CMP Pharma, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CMP Pharma, Inc. \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by CMP Pharma, Inc.

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Atorvaliq (atorvastatin calcium) is the first and only FDA-approved oral liquid Suspension that is indicated for the treatment of high cholesterol and certain risk factors for heart disease or stroke.

                          Brand Name : Atorvaliq

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 23, 2023

                          Lead Product(s) : Atorvastatin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Liqrev (sildenafil) is the PDE5 inhibitor and First and Only Ready-made FDA-approved Liquid Suspension is indicated for the treatment of pulmonary arterial hypertension.

                          Brand Name : Liqrev

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 21, 2023

                          Lead Product(s) : Sildenafil Citrate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Potassium phosphate injection is a phosphate replacement that is used to treat or prevent hypophosphatemia (low phosphorus in the blood).

                          Brand Name : Potassium Phosphate-Geneic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 31, 2023

                          Lead Product(s) : Potassium Phosphate

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Tadliq is the first and only FDA-approved liquid oral suspension of tadalafil for adult patients with difficulty swallowing. Tadliq is indicated for the treatment of pulmonary arterial hypertension and ensures consistent dosing.

                          Brand Name : Tadliq

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 24, 2022

                          Lead Product(s) : Tadalafil

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Norliqva (Amlodipine) oral solution, 1 mg/mL, first and only FDA-approved oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker, for treatment of hypertension in patients 6 years of age and older.

                          Brand Name : Norliqva

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 01, 2022

                          Lead Product(s) : Amlodipine Besylate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank